AbbVie Inc. vs Berkshire Hathaway Inc.: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and Berkshire Hathaway Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating Berkshire Hathaway Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and Berkshire Hathaway Inc. is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $371.4B for Berkshire Hathaway Inc., while their respective market capitalizations stand at $451.5B and $1.05T. AbbVie Inc. is headquartered in United States and Berkshire Hathaway Inc. operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

Berkshire Hathaway Inc.: Berkshire began as a textile company and became a holding company after Warren Buffett gained control in 1965. The modern company is a collection of operating businesses and investments bound by decentralized management, conservative financing, and a long-term shareholder culture.

AbbVie Inc. and Berkshire Hathaway Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and Berkshire Hathaway Inc..

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

Berkshire Hathaway Inc. business model: Berkshire makes money through insurance underwriting and float investment, freight rail, regulated utilities and energy infrastructure, industrial manufacturing, wholesale distribution, retail, services, and a large portfolio of equity and fixed-income investments.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of Berkshire Hathaway Inc..

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

Berkshire Hathaway Inc. competitive advantage: Berkshire's advantage is permanent capital, insurance float, a conservative balance sheet, reputation with sellers, and a decentralized culture that attracts owner-minded managers.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and Berkshire Hathaway Inc. each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

Berkshire Hathaway Inc. growth strategy: Berkshire's growth strategy is not a top-down operating plan; it is disciplined capital allocation. The company reinvests in subsidiaries, buys public equities, acquires private businesses when prices fit, and keeps a fortress balance sheet for downturns.

A closer look at the financial trajectory of AbbVie Inc. and Berkshire Hathaway Inc. rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

Berkshire Hathaway Inc.: For FY2025, Berkshire reported $371.444B in revenue and $66.968B in net income attributable to shareholders. Its filing reported about 387,800 employees worldwide at year-end. The updated net income replaces the prior-year comparison figure previously used in this profile.